How Good Is Semaglutide, Really? The Trial Evidence Explained

What the STEP 1 trial tells us — and what it doesn't

The STEP 1 study is the anchor piece of evidence for semaglutide as a weight-management medicine. Roughly 1,900 adults with obesity but without type 2 diabetes were randomised to either semaglutide 2.4 mg or placebo for 68 weeks, all alongside a reduced-calorie diet and increased activity. Average weight loss in the semaglutide group came to approximately 15%, compared with under 3% in the placebo group. That gap is large enough to be clinically meaningful rather than statistically marginal.

What the trial also showed is that this is not a medicine people respond to uniformly. A substantial proportion achieved more than 15% loss; others lost considerably less. The 15% figure is an average across a real, varied population — useful as a benchmark, but not a personal forecast. Results depend on adherence, the dose reached, background health, and the lifestyle changes made alongside treatment. That is why whether semaglutide is a good weight-loss drug for a specific person is genuinely a clinical question, not one a webpage can settle.

NICE reviewed this evidence in depth before publishing its recommendation for semaglutide (as Wegovy) in 2023. Its conclusion, set out in NICE technology appraisal TA875, was that semaglutide is recommended, but only within specialist weight-management services and for a maximum of two years on the NHS. That time limit matters. Weight can return after stopping, which is one reason ongoing clinical oversight is built into any responsible treatment programme.

How semaglutide compares with what came before

To put the 15% figure in context: older weight-management medicines rarely moved the needle much beyond 5–8% average weight reduction. Reaching 15% average loss in a trial population shifted how clinicians, NICE, and the NHS think about pharmacological treatment for obesity. The NHS has historically framed obesity medicines as a short-term adjunct; semaglutide's results pushed that framing.

The only head-to-head trial directly comparing semaglutide 2.4 mg with tirzepatide (Mounjaro) is SURMOUNT-5, published in the New England Journal of Medicine in 2025. Tirzepatide produced greater average weight reduction than semaglutide at the doses studied. Some researchers note that the newer 7.2 mg semaglutide dose (approved by the MHRA in early 2026) narrows that gap, though head-to-head data at 7.2 mg are not yet available. If you want a side-by-side look at the strengths and limitations of Wegovy in plain terms, that page covers both angles without editorialising.

For most people weighing up their options, the honest answer is that both medicines are considerably more effective than anything previously available outside a surgical setting, and the right choice depends on individual health profile, contraindications, and what a prescriber concludes after a proper assessment.

What semaglutide is good for, and where it has limits

Semaglutide under the Wegovy brand is licensed in the UK for weight management in adults. That is what it is approved for when prescribed at the 2.4 mg (or now up to 7.2 mg) weekly dose. A separate brand, Ozempic, contains semaglutide at lower doses and is licensed for type 2 diabetes; it is not a weight-loss medicine in regulatory terms and should never be prescribed as one.

Beyond weight, semaglutide holds a UK authorisation for reducing major cardiovascular event risk in eligible adults, and from July 2026 a conditional approval for a form of fatty liver disease (MASH). These are separate indications; if you are looking at semaglutide specifically for weight management, the Wegovy licence is the relevant one.

Semaglutide is not suitable for everyone. It is not licensed for under-18s. It is not recommended during pregnancy, while breastfeeding, or for anyone actively trying to conceive. Certain conditions (including a personal or family history of medullary thyroid carcinoma, or a history of pancreatitis) require a prescriber to look carefully before proceeding. Side effects are predominantly gastrointestinal: nausea, loose stools, indigestion, and reduced appetite are common, particularly in the first weeks after starting or after a dose increase. These often ease with time, though some people find them persistent enough to stop treatment.

Storage is straightforward once you know the routine: Wegovy injection pens are kept in the fridge, typically in the door next to everyday items, and taken out only for the weekly injection. The oral Wegovy tablet requires no refrigeration at all, which some people find easier to manage day to day. For anything related to semaglutide's mechanism, schedule, and practical use, that page goes into detail on all of it.

The private route: what to consider before starting

On the NHS, access to semaglutide for weight management runs through specialist services under NICE TA875, and waiting lists in many areas are long. Private prescribing removes the referral barrier, but it does not remove the clinical one. A prescriber still needs to confirm that semaglutide is appropriate, review your health history, and check for contraindications. That assessment is not optional: semaglutide is a prescription-only medicine and the assessment is what the prescription exists to ensure.

At nume, a GPhC-registered Independent Prescriber reviews every consultation personally on the day it is submitted, no automated decisions, no overnight queue. If you want to understand what the full treatment assessment process involves before you commit to anything, that page lays out each step plainly. A look at what to expect when buying Wegovy through a regulated UK pharmacy covers the practical and safety side in more detail.

Cost is a fair question. Private semaglutide treatment has a price that reflects the medicine, the prescription, and the clinical oversight, and if you are wondering whether Wegovy is any good as a treatment before committing to the expense, that page works through the evidence honestly. Whether Wegovy is worth it for a given person is partly a clinical calculation and partly a personal one, and our prescribers are there to help with the first part. If you are ready to find out whether semaglutide is suitable for you, start your free consultation and a prescriber will review your answers the same day.